Bioventus Inc. (BVS)

NASDAQ • Healthcare

$13.2

+$0.19 (+1.5%)

Market closed

Last close at September 16, 2026 at 20:00 UTC

Open$13.02

Day Range$12.98 - $13.33

Avg. Volume (3M)537.7K

Market Cap$894.9M

P/E Ratio16.5

52 Week Range

$6.26$15.89

Next EarningsIn 48 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$153.2M100%

Gross Profitminus cost of goods$105.6M69%

Operating Incomeminus R&D and overhead$19.1M12%

Net Incomeminus taxes and the rest$33.4M22%

In plain terms: out of every $100 in revenue, Bioventus Inc. keeps $22 as net profit.

Fundamentals & Financials

Revenue (TTM)

$581.8M

Net Income (TTM)

$54.4M

EPS (TTM)

$0.8

ROA (TTM)

8.09%

Current Ratio

1.69

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-4.5%Q3 2025$0.21

-30.2%Q4 2025$0.15

+9.1%Q1 2026$0.24

+66.7%Q2 2026$0.15

+1.7%Q3 2026$0.22

Nov 3

in 48 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +1.7%

Bioventus’s adjusted EPS edged past consensus while revenue came in slightly below expectations in the second fiscal quarter of 2026, reported Aug. 5, with adjusted EPS of $0.22 versus the $0.22 estimate, about +1.7%, and up 4.8% from $0.21 a year ago. Revenue rose 3.8% to about $153.2 million from about $147.7 million a year earlier, but it missed the about $154.9 million consensus by 1.1%. Gross profit came in at about $105.7 million, leaving gross margin near 69%, and operating income was about $19.1 million with operating margin around 12.5%. The quarter also generated operating cash flow of about $28.8 million. Next-period consensus calls for EPS of $0.17 on revenue of $149.0 million.

View full earnings history

About Bioventus Inc.

Bioventus Inc. (NASDAQ: BVS) develops and sells medical devices and restorative therapies aimed at pain relief and musculoskeletal care. Its portfolio spans osteoarthritis injections, peripheral nerve stimulation, surgical systems, bone graft substitutes, and bone healing products, and produced $568.1 million of revenue in FY2025.

Name

Bioventus Inc.

CEO

Robert Claypoole

Website

www.bioventus.com

Industry

Healthcare

Year Founded

2011

Employees

950

Today's Snapshot

AI-generated

BVS closed 1.5% higher at 13.20, while its sector was flat.

Trading Volume

Above 10d avg 507.9K

546K

vs S&P 500 Today

Outperforming Market

+2.12%

Updated: September 16, 2026 at 20:40 UTC

Technical Indicators

3 Buy2 Neutral3 Sell

BVS presents a neutral technical profile with a tepid trend—ADX just under 24—while momentum is mixed and leaning slightly negative as MACD and a commodity‑channel indicator are bearish and the RSI sits in the mid‑40s. Price is close to short-term averages but remains well above the 200‑day level, producing a split between near-term softness and longer-term support. Volume trends are unfavorable and volatility is moderate with an ATR near 0.52. The classic pivot is modestly below the market. Technical takeaway: the indicators balance into a neutral stance rather than a clear directional bias.

All signals